Chong Kim

Dr. Chong Kim


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020
Verified
Journal Article
Closed access
SWSayed Emal Wahezi
Sayed Emal Wahezi
RDRui Duarte
Rui Duarte
SYSandeep Yerra
Sandeep Yerra
MTMark A. Thomas
Mark A. Thomas
BPBeendu Pujar
Beendu Pujar
Alan David KayeAlan David Kaye
Alan David Kaye

16 December 2021 in Ochsner Journal
Verified
Journal Article
Open access
PDF file
MGMaria Grabnar
Maria Grabnar
MRMary Joan Roach
Mary Joan Roach
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
CKChong Kim
Chong Kim
Background: To reduce pain and anxiety associated with interventional pain procedures, sedation is often used, with benzodiazepines, opioids, and propofol the most commonly used classes of drugs for sedation. However, patient coherence and ability to communicate procedural pain and abnormal sensations help prevent adverse outcomes. Therefore, discovering alternative therapies to mitigate the anxiety and pain associated with these procedures and to minimize risk is important. The aim of our study was to investigate whether lavender has an effect on pain and anxiety associated with lumbar epidural steroid injections and lumbar medial branch blocks. Methods: In this randomized controlled study, 54 subjects were randomly assigned to 1 of 3 intervention groups, and 46 patients were included in the final analysis: experimental lavender group (n=17), control almond oil group (n=15), and placebo sterile water group (n=14). Patients wore a mask infused with either lavender, almond oil, or water for 5 minutes prior to and during their procedure. Patients rated their anxiety using the State-Trait Anxiety Inventory prior to and after the procedure based on how they felt during the procedure. Patients rated their pain according to the numerical rating scale. Outcome measures were a comparison of pain among the 3 groups and a comparison of the change in anxiety before and after the procedure among the 3 groups. Results: The lavender group demonstrated the highest mean change in anxiety scores (9.9) compared to almond oil (5.3) and water (3.6) preprocedurally vs postprocedurally. The lavender group also reported the lowest mean pain level (3.8) compared to almond oil (5.6) and water (5.6). However, none of the differences between groups showed statistical significance at the P<0.05 level. Conclusion: Lavender may have a clinically beneficial effect on anxiety levels and pain reduction.

20 July 2020 in American Journal of Physical Medicine & Rehabilitation
Verified
Journal Article
Closed access
MGMaria Grabnar
Maria Grabnar
CKChong Kim
Chong Kim
Chemotherapy-induced neuropathy has limited treatment options, and conventional medications used to treat neuropathic pain often do not provide adequate pain relief for patients with a history of cancer. Neuromodulation such as dorsal root ganglion stimulation remains a treatment that has been studied for chronic painful conditions such as low back pain, pelvic pain, complex regional pain syndrome, and phantom limb pain. Dorsal root ganglion stimulation has been presented for treatment of chemotherapy-induced neuropathy, but with limited duration of follow-up. We present a case of pain resolution after placement of a dorsal root ganglion stimulation for persistent chemotherapy-induced neuropathy. Our patient developed burning pain and allodynia in both feet 3 mos into her chemotherapy regimen, with worsened symptoms after cessation of chemotherapy. After failure of conservative pharmacotherapies, a 7-day dorsal root ganglion stimulation trial was implanted, resulting in 100% pain relief. A dorsal root ganglion stimulation was then implanted permanently, and our patient reported continued resolution of symptoms at evaluation 3 yrs after placement. To the author’s knowledge, this is the first case of sustained relief with dorsal root ganglion stimulation placement for chemotherapy-induced neuropathy and presents a treatment option that warrants further investigation.

6 March 2020 in Trials
Verified
Journal Article
Open access
PDF file
TCTravis Cleland
Travis Cleland
NJNitin B Jain
Nitin B Jain
JCJohn Chae
John Chae
KHKristine M. Hansen
Kristine M. Hansen
THTerri Z. Hisel
Terri Z. Hisel
RWRichard D. Wilson
Richard D. Wilson
Background: Shoulder impingement syndrome is one of the most common causes of shoulder pain, accounting for approximately 30% of all shoulder pain. Approximately 35% of patients with shoulder impingement syndrome are refractory to conservative treatment. For patients who fail conservative treatment, there is no established treatment to successfully treat their chronic pain. Prior randomized control trials have demonstrated efficacy for the use of a single lead intramuscular peripheral nerve stimulation of the axillary nerve at the motor points of the deltoid muscle for treatment of hemiplegic shoulder pain. This is the first controlled trial to utilize the same novel technology to treat shoulder impingement syndrome outside of the stroke population. Methods: This is a dual-site, placebo-controlled, double-blinded, randomized control trial. Participants will be randomized to two treatment groups. The intervention group will be treated with active peripheral nerve stimulation of the axillary nerve of the affected shoulder and the control group will be treated with sham peripheral nerve stimulation of the axillary nerve of the affected shoulder. Both groups will receive a standardized exercise therapy program directed by a licensed therapist. Discussion: This study protocol will allow the investigators to determine if this novel, non-pharmacologic treatment of shoulder pain can demonstrate the same benefit in musculoskeletal patients which has been previously demonstrated in the stroke population. Trial registration: Clinicaltrials.gov, NCT03752619. Registered on 26 November 2018.

31 July 2024 in American Journal of Physical Medicine & Rehabilitation
Verified
Journal Article
Closed access
NENafis B. Bs Eghrari
Nafis B. Bs Eghrari
MCMatthew Ba Chen
Matthew Ba Chen
CKChong Kim
Chong Kim
Objective: This study aimed to evaluate the association between body mass index and postoperative opioid use within 2 yrs after lumbar spine surgery using a national database. Methods: TriNetX, a national network of deidentified patient records, was retrospectively queried from 2003 to 2021 using International Classification of Disease 10, Current Procedural Terminology, and Veterans Affairs codes. Propensity score matching analysis was performed based on demographics, comorbidities, anxiety disorders, and mood disorders. Results: A total of 21,997 patients were included in our analysis. Patients with body mass index ≥ 30 were more likely to be prescribed opioids postoperatively (odds ratio: 1.30; 95% confidence interval: 1.18–1.42). Patients with body mass index ≥ 40 were more likely to be prescribed opioids when compared to patients with body mass index < 30 (odds ratio: 1.94; 95% confidence interval: 1.48–2.56), body mass index 30–34.9 (odds ratio: 2.06; 95% confidence interval: 1.57–2.70), body mass index 35–39.9 (odds ratio: 1.50; 95% confidence interval: 1.13–2.00), and body mass index < 40 (odds ratio: 2.06; 95% confidence interval: 1.57–2.70). The body mass index ≥ 40 group had an increased number of opioid prescriptions within 2 yrs after lumbar surgery compared to patients with body mass index 30–34.9 (P = 0.0113) and body mass index < 30 (P = 0.0018). Conclusions: Opioid prescription after lumbar spine surgery is associated with an elevated body mass index. Patients with class III obesity seem to be at the highest risk of increased opioid prescriptions after lumbar surgery. Physicians should consider the patient’s body mass index when deciding postoperative pain management.

30 June 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SSSuzanna Shermon
Suzanna Shermon
KFKimberly Michelle Fazio
Kimberly Michelle Fazio
RSRichard Shim
Richard Shim
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
CKChong Kim
Chong Kim
Objective: The objective of this study was to evaluate discrepancies in prescription trends for analgesic medications in complex regional pain syndrome (CRPS) patients based on recommendations in the literature. Design: We conducted a retrospective case–control study. Subjects: A total of 2510 CRPS patients and 2510 demographic-matched controls participated in this study. Methods: The SlicerDicer feature in Epic was used to find patients diagnosed with CRPS I or II between January 2010 and November 2022. An equal number of age-, gender-, and race-matched controls without a CRPS diagnosis were retracted from Epic. General and CRPS-associated prescription frequencies for the following classes were retrieved for both cases and controls: benzodiazepines, bisphosphonates, calcitonin, capsaicin, neuropathic pain medications, NSAIDs, opioids, and steroids. Results: A total of 740 (29%) CRPS patients and 425 (17%) controls were prescribed benzodiazepines (95% CI 0.1–0.15), 154 (6.1%) CRPS patients and 52 (2.1%) controls were prescribed capsaicin (95% CI 0.03–0.05), 1837 (73%) CRPS patients and 927 (37%) controls were prescribed neuropathic pain medications (95% CI 0.05–0.34), 1769 (70%) CRPS patients and 1217 (48%) controls were prescribed opioids (95% CI 0.19–0.25), 1095 (44%) CRPS patients and 1217 (48%) controls were prescribed steroids (95% CI 0.08–0.14), and 1638 (65%) CRPS patients and 1765 (70%) controls were prescribed NSAIDs (95% CI −0.08–0.02), p < 0.001 for all classes. With CRPS-associated prescriptions, (95% CI 0.05–0.16, p < 0.001) more CRPS patients were prescribed opioids (N = 398, 59%) than controls (N = 327, 49%). Conclusions: CRPS is difficult to treat with significant variance in suggested treatment modalities. Based on the results of our study, there is a divergence between some published recommendations and actual practice.